

3	Rationale		
3	Objective	3	Figures
3	Methodology	5	Figure 1: Participants
4	Results	9	Figure 2: Use of Foam Sclerotherapy
4	1. General Questions	12	Figure 3: Necessity of foam standardization
4	1.1 Indications for Foam Sclerotherapy	13	Figure 4: Average foam volumes for GSV per puncture
4	1.2 Experts' experience	14	Figure 5: Maximum foam volumes for GSV per puncture
4	1.3 Number of treated patients	21	Figure 6: Different maximum foam volumes per session in C ₁ - and C ₂ -varicose veins
			Figure 7: Compression after Foam Sclerotherapy
4	2. Access Material		
5	3. Access Location		
6	4. Sclerosant Foam Preparation	3	Tables
7	4.1 Methods of sclerosant foam preparation	4	Table I: Participant
8	4.2 Gases for sclerosant foam preparation	5	Table II: Topics of the 2 nd ECMFS
8	4.3 Relation of liquid and gas	6	Table III: Number of treated patients
8	4.4 Drug	6	Table IV: Access material for Foam Sclerotherapy
9	4.5 Miscellaneous	6	Table V: Access material (needles)
		8	Table VI: Methods of sclerosant foam preparation
		8	Table VII: Foam preparation – used gas fraction
9	5. Concentrations	9	Table VIII: Liquid plus air ratios used
9	5.1 Concentrations of Polidocanol	10	Table IX: Concentrations of Polidocanol / Indication
10	5.2 Concentrations of Sodium Tetradecyl Sulphate	11	Table X: Concentrations of Polidocanol / Diameter
		11	Table XI: Concentrations of STS / Indication
10	6. Foam Volumes	11	Table XII: Concentrations of STS / Diameter
		13	Table XIII: Foam volumes per puncture
14	7. Efficacy of Foam Sclerotherapy	22	Table XIV: Compression material after Foam Sclerotherapy
14	7.1 Immediate signs after Foam Sclerotherapy	24	Table XV: Definition / grading of the therapeutic effects of Foam Sclerotherapy
15	7.2 Evaluation of the therapeutic effects of Foam Sclerotherapy		
			Consensus
15	8. Safety Aspects of Foam Sclerotherapy	7	Consensus 1: Access location for GSV treatment
15	8.1 Safety aspects of Foam Sclerotherapy in GSV and SSV	7	Consensus 2: Access location for SSV treatment
16	8.2 Safety aspects of Foam Sclerotherapy in Reticular Veins	7	Consensus 3: Access location for treatment of Perforating Veins
16	8.3 Safety aspects of Foam Sclerotherapy in Telangiectasia	8	Consensus 4: Methods of sclerosant foam preparation
16	8.4 Safety aspects of Foam Sclerotherapy in Venous Vascular Malformations	8	Consensus 5: Gas used to prepare sclerosant foam
17	8.5 Body position in Foam Sclerotherapy	8	Consensus 6: Ratio of liquid and gas for sclerosant foam preparation
17	8.6 Compression of junctions in Foam Sclerotherapy	9	Consensus 7: Standardisation of sclerosant foam preparation
18	8.7 Additional safety measures in Foam Sclerotherapy	10	Consensus 8: Concentrations of Polidocanol / Indication
		12	Consensus 9: Foam volumes per puncture
18	9. Contraindications	12	Consensus 10: Maximum foam volume per leg
18	9.1 Patent Foramen Ovale and Migraine	13	Consensus 11: Maximum foam volume per session
19	9.2 Thromboembolism and thrombophilia	14	Consensus 12: Foam quality for treatment of large veins
20	9.3 Other relative and absolute contraindications	15	Consensus 13: Evaluation of the therapeutic effects of Foam Sclerotherapy
		15	Consensus 14: Evaluation of short-term therapeutic effects
21	10. Compression after Foam Sclerotherapy	15	Consensus 15: Evaluation of mid- and long-term therapeutic effects
		16	Consensus 16: Increasing safety during GSV or SSV treatment with Foam Sclerotherapy
22	11. Patient Information	16	Consensus 17: Increasing safety during Reticular Vein treatment with Foam Sclerotherapy
		17	Consensus 18: Increasing safety during Telangiectasia treatment with Foam Sclerotherapy
22	12. Endovenous Catheter Techniques		
23	13. Duplex Ultrasound in Foam Sclerotherapy		
25	14. Miscellaneous		
25	Acknowledgment		